Recombinant human erythropoietin in the treatment of acute ischemic stroke

Stroke

Volumn 40, Issue 12, 2009, Pages

  Ehrenreich, Hannelore ^a   Weissenborn, Karin ^b   Prange, Hilmar ^c   Schneider, Dietmar ^d   Weimar, Christian ^e   Wartenberg, Katja ^f   Schellinger, Peter D ^g   Bohn, Matthias ^c   Becker, Harald ^h   Wegrzyn, Martin ^a   Jähnig, Peter ⁱ   Herrmann, Manfred ^j   Knauth, Michael ^c   Bähr, Mathias ^c   Heide, Wolfgang ^k   Wagner, Armin ^d   Schwab, Stefan ^g   Reichmann, Heinz ^f   Schwendemann, Günther ^j   Dengler, Reinhard ^b   Kastrup, Andreas ^c   Bartels, Claudia ^a   more..

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h Applied Science and Technology   (Germany)

ⁱ PAREXEL INTERNATIONAL   (United States)

^j UNIVERSITY OF BREMEN   (Germany)

^k ALLGEMEINES KRANKENHAUS CELLE   (Germany)

more..

Author keywords

Clinical trial; Hematopoietic growth factor; Neuroprotection; NIHSS; RtPA

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT; COUMARIN DERIVATIVE; EPOETIN ALPHA; HEPARIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTERY OCCLUSION; ARTICLE; ASPIRATION PNEUMONIA; BARTHEL INDEX; BLOOD CLOT LYSIS; BRAIN EDEMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; FEMALE; GERMANY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SEIZURE; SEPSIS; SPLEEN INFARCTION; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; THROMBOSIS;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG TOXICITY; ERYTHROPOIETIN; FEMALE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORTALITY; NEUROPROTECTIVE AGENTS; PATIENT SELECTION; PLACEBO EFFECT; RECOMBINANT PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70949095435     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.564872     Document Type: Article

References (31)

1. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
2. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck H-H, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren A-L. Erythropoietin therapy for acute stroke is both safe and beneficial. Molecular Medicine. 2002;8: 495-505.
3. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6:484-494.
4. Juul S. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol. 2004;31:129-142.
5. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526-10531.
6. Ehrenreich H, Degner D, Meller J, Brines M, Béhé M, Hasselblatt M, Woldt H, Falkai P, Knerlich F, Jacob S, Von Ahsen N, Maier W, Brück W, Ruther E, Cerami A, Becker W, Siren A-L. Erythropoietin. A candidate compound for neuroprotection in schizophrenia. Molecular Psychiatry. 2004;9:42-54.
7. Banks WA, Jumbe NL, Farrell CL, Niehoff ML, Heatherington AC. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol. 2004;505:93-101.
8. Weimar C, Kraywinkel K, Maschke M, Diener HC. Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator. Cerebrovasc Dis. 2006;22: 429-431.
9. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
10. Lan KK, Zucker DM. Sequential monitoring of clinical trials: the role of information and brownian motion. Stat Med. 1993;12:753-765.
11. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20: 864-870. (Pubitemid 19188240)
12. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
13. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Inter-observer agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
14. Anonymous. SITS-MOST (EMEA) study protocol. Available at: www. Acutestroke.Org/index.Php?Module=contentexpress&func=display&ceid= 29&meid=6. 2002. Accessed August 25th, 2009.
15. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
16. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U. Nxy-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
17. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. Dp-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke. 2008;39:1774-1778.
18. Kaste M. Thrombolysis: what more does it take? Stroke. 2005;36: 200-202.
19. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
20. Bravata DM. Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice. CNS Drugs. 2005;19:295-302.
21. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
22. Gomez-Choco M, Obach V, Urra X, Amaro S, Cervera A, Vargas M, Chamorro A. The response to IV rt-PA in very old stroke patients. Eur J Neurol. 2008;15:253-256.
23. Schmülling S, Rudolf J, Strotmann-Tack T, Grond M, Schneweis S, Sobesky J, Thiel A, Heiss WD. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2003;16:183-190.
24. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a phase II randomized, double-blind, placebo-controlled trial. J Neurosurg. 2009;111:171-180.
25. Johnston KC, Wagner DP, Wang XQ, Newman GC, Thijs V, Sen S, Warach S. Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome? Stroke. 2007;38:1820-1825.
26. Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, Bucher HU. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008;122:375-382.
27. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
28. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924.
29. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with meta-static breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960-5972.
30. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN. Randomized, double-blind, placebo-controlled trial of eryth-ropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-1032.
31. Dronca RS, Steensma DP. VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia. Nat Clin Pract Oncol. 2008;5:504-505.